The company said net sales for fiscal 2024 Q3 rose 3% to $303.4 million, with organic revenue up 2% from a year earlier and acquisitions adding 1%. It said foreign exchange and the business held for sale did not have a material impact.

1. 01

   The company said net sales for fiscal 2024 Q3 rose 3% to $303.4 million, with organic revenue up 2% from a year earlier and acquisitions adding 1%. It said foreign exchange and the business held for sale did not have a material impact.

2. 02

   The company said GAAP operating income for Q3 fell 16% to $67.0 million, with an operating margin of 22.1%. Adjusted operating income decreased 8% to $99.6 million, with an adjusted operating margin of 33.0% compared with 37.0% a year earlier. It cited the acquisition of Lunaphore among the factors.

3. 03

   The company said GAAP diluted earnings per share for Q3 were $0.31, lower than $0.43 a year earlier, and adjusted diluted earnings per share were $0.48, lower than $0.53 a year earlier.

4. 04

   The company said net sales in the Diagnostics and Genomics segment for Q3 rose 16% to $87.5 million (organic 10%), and the segment's operating margin was 9.3%, lower than 15.2% a year earlier. The company cited the Lunaphore acquisition as the reason for the decline in operating margin.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.